TrialsgrambetaRCTs are beautiful

CLEAR Outcomes

2023

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

In 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.

Result

Efficacy: CV death, MI, stroke or coronary revascularisationHR 0.87

Below 1 favours bempedoic acid, above 1 favours placebo.

Event rates
Absolute difference
1.6 points

The absolute difference is derived from the event rates.

Also reported: No new-onset diabetes; gout and tendon-rupture signals.

Original publication
Subtopic
Non-statin LDL
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Nissen SE, et al. N Engl J Med. 2023;388(15):1353-1364.doi 10.1056/NEJMoa2215024

Discussion & critique

Provides an outcomes-proven non-statin oral option for the genuinely statin-intolerant. The effect size is modest; the primary-prevention subgroup did better.

Discussed in podcasts